Clostridium Difficile

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection

Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections

Immune Response to C.Difficile Infection

Antimicrobial Stewardship Program for Clostridium Difficile Infection.

Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation